A two-step clinical study in HIV-positive subjects to assess PENNVAX-GP with INO-9012 alone and with the addition of a PD-1 checkpoint inhibitor

Trial Profile

A two-step clinical study in HIV-positive subjects to assess PENNVAX-GP with INO-9012 alone and with the addition of a PD-1 checkpoint inhibitor

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs HIV clades A C B DNA vaccine Inovio (Primary) ; INO 9012 (Primary)
  • Indications HIV infections
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 New trial record
    • 30 Mar 2017 According to an Inovio Pharmaceuticals media release, this trial will be conducted at the University of California in San Fransisco and Los Angeles.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top